Orient EuroPharma Past Earnings Performance
Past criteria checks 1/6
Orient EuroPharma's earnings have been declining at an average annual rate of -35.8%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been declining at an average rate of 6.5% per year. Orient EuroPharma's return on equity is 4.3%, and it has net margins of 4.3%.
Key information
-35.8%
Earnings growth rate
-35.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | -6.5% |
| Return on equity | 4.3% |
| Net Margin | 4.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why Orient EuroPharma (GTSM:4120) Has A Meaningful Debt Burden
Apr 04
Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) 3.3% Dividend Worth Your Time?
Mar 04A Look At Orient EuroPharma's (GTSM:4120) Share Price Returns
Feb 10Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) Recent Performancer Underpinned By Weak Financials?
Jan 22We Think Orient EuroPharma (GTSM:4120) Can Stay On Top Of Its Debt
Jan 04
A Look At The Fair Value Of Orient EuroPharma Co., Ltd. (GTSM:4120)
Dec 17Are Dividend Investors Getting More Than They Bargained For With Orient EuroPharma Co., Ltd.'s (GTSM:4120) Dividend?
Nov 29Revenue & Expenses Breakdown
How Orient EuroPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,471 | 191 | 1,797 | 262 |
| 30 Jun 24 | 4,499 | 145 | 1,807 | 248 |
| 31 Mar 24 | 4,545 | 26 | 1,843 | 252 |
| 31 Dec 23 | 4,592 | 144 | 1,870 | 207 |
| 30 Sep 23 | 4,663 | -246 | 1,967 | 217 |
| 30 Jun 23 | 4,668 | -398 | 2,009 | 214 |
| 31 Mar 23 | 4,738 | -307 | 1,995 | 235 |
| 31 Dec 22 | 4,730 | -311 | 1,922 | 260 |
| 30 Sep 22 | 4,727 | -93 | 1,897 | 253 |
| 30 Jun 22 | 4,767 | 47 | 1,854 | 291 |
| 31 Mar 22 | 4,696 | 138 | 1,869 | 307 |
| 31 Dec 21 | 4,767 | 120 | 1,915 | 331 |
| 30 Sep 21 | 4,808 | -82 | 1,921 | 408 |
| 30 Jun 21 | 4,835 | -48 | 1,959 | 408 |
| 31 Mar 21 | 5,049 | 87 | 1,918 | 371 |
| 31 Dec 20 | 5,384 | 199 | 1,938 | 367 |
| 30 Sep 20 | 5,664 | 266 | 656 | 345 |
| 30 Jun 20 | 5,966 | 311 | 655 | 345 |
| 31 Mar 20 | 6,141 | 236 | 736 | 373 |
| 31 Dec 19 | 6,093 | 248 | 747 | 395 |
| 30 Sep 19 | 5,929 | 233 | 877 | 398 |
| 30 Jun 19 | 5,832 | 286 | 841 | 407 |
| 31 Mar 19 | 5,648 | 243 | 748 | 400 |
| 31 Dec 18 | 5,510 | 247 | 663 | 389 |
| 30 Sep 18 | 5,396 | 241 | 1,761 | 422 |
| 30 Jun 18 | 5,363 | 319 | 1,713 | 412 |
| 31 Mar 18 | 5,260 | 418 | 1,675 | 389 |
| 31 Dec 17 | 5,226 | 459 | 1,653 | 379 |
| 30 Sep 17 | 5,272 | 585 | 1,599 | 315 |
| 30 Jun 17 | 5,209 | 504 | 1,595 | 335 |
| 31 Mar 17 | 5,267 | 471 | 1,591 | 355 |
| 31 Dec 16 | 5,232 | 470 | 1,576 | 363 |
| 30 Sep 16 | 5,050 | 362 | 1,539 | 398 |
| 30 Jun 16 | 5,032 | 322 | 1,509 | 408 |
| 31 Mar 16 | 4,878 | 272 | 1,481 | 420 |
| 31 Dec 15 | 4,907 | 223 | 1,478 | 425 |
| 30 Sep 15 | 4,982 | 216 | 1,463 | 383 |
| 30 Jun 15 | 5,035 | 230 | 1,472 | 356 |
| 31 Mar 15 | 5,121 | 253 | 1,476 | 327 |
| 31 Dec 14 | 5,000 | 196 | 1,443 | 332 |
| 30 Sep 14 | 4,851 | 123 | 1,497 | 364 |
| 30 Jun 14 | 4,645 | 195 | 1,495 | 339 |
| 31 Mar 14 | 4,619 | 436 | 1,438 | 312 |
| 31 Dec 13 | 4,665 | 507 | 1,447 | 266 |
Quality Earnings: 4120 has a large one-off gain of NT$234.3M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 4120 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4120's earnings have declined by 35.8% per year over the past 5 years.
Accelerating Growth: 4120 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 4120 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).
Return on Equity
High ROE: 4120's Return on Equity (4.3%) is considered low.